How many insider trades does FilingIQ track for GYRE?

FilingIQ tracks 116 Form 4 insider transactions for GYRE (GYRE THERAPEUTICS, INC.), covering filings from Oct 30, 2023 onwards. 11 of those were filed in the last 90 days.

Are GYRE insiders net buyers or net sellers?

Across the full Form 4 history for GYRE, 0 transactions (0%) were open-market purchases and 94 (81%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does GYRE insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is GYRE in?

GYRE THERAPEUTICS, INC. (GYRE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $411.03M.

GYRE insider trading

NasdaqCM Healthcare

GYRE THERAPEUTICS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

116

Last 90 days

Buys / sells

0% / 81%

Market cap

$411.03M

About GYRE THERAPEUTICS, INC.

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Company website: crescentbiopharma.com

GYRE insider activity at a glance

FilingIQ has scored 116 insider transactions for GYRE since Oct 30, 2023. The most recent filing in our index is dated May 6, 2026.

Across the full history, 0 open-market purchases and 94 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on GYRE insider trades is 64.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live GYRE trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for GYRE?: FilingIQ tracks 116 Form 4 insider transactions for GYRE (GYRE THERAPEUTICS, INC.), covering filings from Oct 30, 2023 onwards. 11 of those were filed in the last 90 days.
Are GYRE insiders net buyers or net sellers?: Across the full Form 4 history for GYRE, 0 transactions (0%) were open-market purchases and 94 (81%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does GYRE insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is GYRE in?: GYRE THERAPEUTICS, INC. (GYRE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $411.03M.

Methodology & sources

Every GYRE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.